MedTrace Logo

A Phase IIa Study of NT-KO-003 for Multiple Sclerosis

NCT01428726 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2014-03-18

No results posted yet for this study

Summary

The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of relapsing remitting multiple sclerosis, comparing two doses versus placebo.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

DRUG

NT-KO-003

NT-KO-003 is a coated tablet, administered once a day

Sponsors & Collaborators

  • Advancell - Advanced In Vitro Cell Technologies, S.A.

    collaborator INDUSTRY

  • Neurotec Pharma

    lead INDUSTRY

Principal Investigators

  • Pablo Villoslada, MD PhD · Hospital Clinic i Provincial de Barcelona, Spain

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01428726 on ClinicalTrials.gov